DK1749031T3 - Anvendelse af en scFv til reduktion af eksisterende biofilm - Google Patents

Anvendelse af en scFv til reduktion af eksisterende biofilm

Info

Publication number
DK1749031T3
DK1749031T3 DK05748130.1T DK05748130T DK1749031T3 DK 1749031 T3 DK1749031 T3 DK 1749031T3 DK 05748130 T DK05748130 T DK 05748130T DK 1749031 T3 DK1749031 T3 DK 1749031T3
Authority
DK
Denmark
Prior art keywords
scfv
reduce existing
existing biofilms
biofilms
reduce
Prior art date
Application number
DK05748130.1T
Other languages
English (en)
Inventor
Keith Charlton
Andrew Porter
Lorna Thornthwaite
Original Assignee
Haptogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haptogen Ltd filed Critical Haptogen Ltd
Application granted granted Critical
Publication of DK1749031T3 publication Critical patent/DK1749031T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05748130.1T 2004-05-15 2005-05-13 Anvendelse af en scFv til reduktion af eksisterende biofilm DK1749031T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410958.3A GB0410958D0 (en) 2004-05-15 2004-05-15 Methods for reducing biofilm formation in infectious bacteria
PCT/GB2005/001843 WO2005111080A2 (en) 2004-05-15 2005-05-13 Methods for reducing biofilm formation in infectious bacteria

Publications (1)

Publication Number Publication Date
DK1749031T3 true DK1749031T3 (da) 2013-09-23

Family

ID=32527168

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05748130.1T DK1749031T3 (da) 2004-05-15 2005-05-13 Anvendelse af en scFv til reduktion af eksisterende biofilm

Country Status (12)

Country Link
US (1) US20090117109A1 (da)
EP (2) EP1749031B1 (da)
JP (2) JP2008502710A (da)
KR (2) KR20130036365A (da)
CN (1) CN1984929A (da)
AU (1) AU2005243459B2 (da)
CA (1) CA2566588A1 (da)
DK (1) DK1749031T3 (da)
ES (1) ES2427933T3 (da)
GB (1) GB0410958D0 (da)
NO (1) NO20065671L (da)
WO (1) WO2005111080A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100602A1 (en) * 2008-03-12 2009-09-16 QuoNova Europe GmbH Method and compositions suitable for treatment of wounds
KR100868574B1 (ko) * 2008-03-17 2008-11-13 한국광해관리공단 토양 입자 표면에 형성된 바이오필름의 함량 측정 방법
CN102388064A (zh) * 2009-03-27 2012-03-21 高裘企业公司 用于筛选与使用拮抗孢子-表面交互作用的化合物的组合物与方法
US20120097606A1 (en) * 2009-06-22 2012-04-26 Sumitomo Heavy Industries, Ltd. Method for treating wastewater containing ammonia nitrogen
WO2012058531A2 (en) * 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
EP2655402A1 (en) * 2010-12-23 2013-10-30 Intercell Austria AG Oprf/i agents and their use in hospitalized and other patients
JP2014506923A (ja) 2011-03-01 2014-03-20 クオラム イノベーションズ リミテッド ライアビリティ カンパニー 病原性バイオフィルムと関連した状態を治療するための物質および方法
US9387189B2 (en) 2013-05-22 2016-07-12 Professional Compounding Centers Of America (Pcca) Antibiotic composition comprising a chemotactic agent and a nutrient dispersion
NO342374B1 (en) * 2016-07-08 2018-05-14 Inhibio As Compounds and compositions for biofilm prevention
KR102305308B1 (ko) * 2019-06-12 2021-09-27 서정옥 좌석용 헤드레스트 목베개
US20240123101A1 (en) * 2022-10-13 2024-04-18 Hossam Abdel Salam El Sayed Mohamed System and method for prevention of corrosive biofilm formation in petroleum holding or carrying structures

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU753329C (en) * 1997-06-18 2003-05-15 Montana State University Homoserine lactones biofilm regulating compounds and their methods of use
US6395282B1 (en) * 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
WO1999061021A1 (fr) * 1998-05-26 1999-12-02 Shionogi & Co., Ltd. Agents de recouvrement de sensibilite aux medicaments destines a des micro-organismes pathogenes resistants
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AU3580800A (en) 1998-11-25 2000-06-26 Mcw Research Foundation, Inc. Method of and compositions for immunization with the (pseudomonas) v antigen
GB9924195D0 (en) 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0007588D0 (en) 2000-03-30 2000-05-17 Univ Nottingham N-Acyl homoserine lactones
US6703513B1 (en) * 2000-06-02 2004-03-09 K-Quay Enterprises Llc Production and use of derivatized homoserine lactones
EP1528935B1 (en) * 2002-08-13 2012-03-21 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria

Also Published As

Publication number Publication date
NO20065671L (no) 2006-12-08
EP1749031B1 (en) 2013-07-17
EP2281839A2 (en) 2011-02-09
KR20130036365A (ko) 2013-04-11
AU2005243459B2 (en) 2011-11-03
WO2005111080A3 (en) 2006-01-12
EP1749031A2 (en) 2007-02-07
JP2008502710A (ja) 2008-01-31
EP2281839A3 (en) 2013-02-27
AU2005243459A1 (en) 2005-11-24
WO2005111080A2 (en) 2005-11-24
ES2427933T3 (es) 2013-11-04
US20090117109A1 (en) 2009-05-07
GB0410958D0 (en) 2004-06-16
KR20070038464A (ko) 2007-04-10
JP2011042651A (ja) 2011-03-03
CN1984929A (zh) 2007-06-20
AU2005243459A2 (en) 2005-11-24
CA2566588A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
DK1749031T3 (da) Anvendelse af en scFv til reduktion af eksisterende biofilm
DK1778618T3 (da) Syntese af triethylentetraminer
DK2015754T3 (da) Anvendelse af dpp-iv-inhibitorer
DK2317851T3 (da) Anvendelse af 5-fluorcytosin som fungicid
DK1802872T3 (da) Rörledning
DK2024504T4 (da) Fremstilling af isoprenoider
DK3225251T3 (da) Modulering af pro-neurotrofinaktivitet
ATE456276T1 (de) Verwendung dekrementeller zuweisungen
DK1931350T3 (da) Administration af inhibitorer af dipeptidylpeptidase
DK2031063T3 (da) Modulatorer af duftreceptorer
DK1763520T3 (da) Anvendelse af trisubstituerede benzopyranoner
DK1951636T3 (da) Fremstilling af cementholdig plade
DK3208269T3 (da) Inhibitorer af c-fms-kinase
DK1898903T3 (da) Inhibitorer af Akt-aktivitet
DK2700786T3 (da) Modifikation af overførselspassage
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1720866T3 (da) Fremgangsmåde
DK2117523T3 (da) Inhibitorer af AKT-aktivitet
DK1979314T3 (da) Indolsulfonamidmodulatorer af progesteronreceptorer
DK2371818T3 (da) Hydroxybenzoatsalte af metanikotinforbindelser
DK1874766T3 (da) Krystallinsk form af en quinolinon-carboxamid-forbindelse
DK2111555T3 (da) Diagnosticering af præeklampsi
DK1940465T3 (da) Ny anvendelse af anti-IL-1beta-antistoffer
DK2350116T3 (da) Behandling af biofilm
DK2153565T3 (da) Valg af transmissionsmodus